Brief: Elicio Therapeutics Announces Positive Recommendation By Idmc To Continue Eli-002 7P Randomized Phase 2 Study In Pancreatic Cancer Without Modifications To Final Analysis
Elicio Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Elicio Therapeutics Reports First Quarter 2025 Financial Results And Provides Corporate Updates
Elicio Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, Apple
Elicio signals delay in mid-stage cancer vaccine study; shares slump
Elicio Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Elicio Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview
Elicio Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Elicio Therapeutics Inc Files For Offering Of Up To 3.4 Million Shares By The Selling Stockholder - SEC Filing
Elicio Therapeutics Inc expected to post a loss of 73 cents a share - Earnings Preview
Brief: Elicio Therapeutics Appoints Robert Connelly As Principal Financial Officer
Elicio Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Elicio Announces Closing Of Private Placement Of $20 Mln Convertible Note
Elicio Therapeutics Inc expected to post a loss of 96 cents a share - Earnings Preview
Brief: Elicio Therapeutics Announces Preliminary Disease-Free Survival Analysis From The Ongoing Amplify-7P Phase 1A Study Of Eli-002 7P
Brief: Elicio Therapeutics Announces Proposed Public Offering
Brief: Elicio Therapeutics Files For Mixed Shelf Of Up To $200 Mln
Brief: Elicio Therapeutics Announces Preliminary Data From The Ongoing Amplify-7P Phase 1A Study Of Eli-002 7P In Patients With mKRAS-driven Solid Tumors